MYAGIOS® PATIENT SUPPORT SERVICES
myAgios® Patient Support Services for PK Deficiency
Fill out the Enrollment Form online to prescribe PYRUKYND.
Enroll Online
It will be automatically processed by myAgios, where a Patient Support Manager (PSM) will then reach out to your patient directly to complete the enrollment.
To learn about disease education support for your patients or their caregivers
PKdeficiency.myAgios.comSingle point of engagement for education, prescription, and access support
Call myAgios at 1-800-951-3889 to learn about centralized enrollment for eligible patients, including education, prescription fulfillment, financial assistance, access, and adherence support.
Access and Benefits Investigation Services
- Support with insurance coverage
- Administer patient assistance programs
Access and Benefits Investigation Services
- Support with insurance coverage
- Administer patient assistance programs
Prescription fulfillment through exclusive specialty pharmacy
- Commercial product dispensing
- Guidance with dosing questions and coordination of refills
Prescription fulfillment through exclusive specialty pharmacy
- Commercial product dispensing
- Guidance with dosing questions and coordination of refills
Dedicated clinically experienced Patient Support Managers (PSM) can offer disease education and resources
- Single point of contact for HCPs and office staff to help patients access program offerings
- Educational resources and information to help patients explore financial assistance
- Learn more about myAgios disease education for patients and caregivers at PKdeficiency.myAgios.com
Dedicated clinically experienced Patient Support Managers (PSM) can offer disease education and resources
- Single point of contact for HCPs and office staff to help patients access program offerings
- Educational resources and information to help patients explore financial assistance
- Learn more about myAgios disease education for patients and caregivers at PKdeficiency.myAgios.com
myAgios can connect patients to financial assistance and coverage support programs to help with access to PYRUKYND, including information about:
The PYRUKYND Copay Program
- This program lowers costs for eligible patients to $0 per prescription if their copay exceeds that amount
Patients participating in government healthcare insurance are not eligible.
The PYRUKYND Copay Program
- This program lowers costs for eligible patients to $0 per prescription if their copay exceeds that amount
Patients participating in government healthcare insurance are not eligible.
The Patient Assistance Program (PAP)
- Offers free prescriptions to eligible uninsured and underinsured patients
The Patient Assistance Program (PAP)
- Offers free prescriptions to eligible uninsured and underinsured patients
To learn more about a patient’s potential eligibility, start by calling myAgios at 1-800-951-3889.
Coverage Interruption Program
- This program offers a free 28-day prescription (allowing 2 refills) for eligible commercially insured patients experiencing a temporary loss or gap in coverage
Patients participating in government healthcare insurance are not eligible.
Coverage Interruption Program
- This program offers a free 28-day prescription (allowing 2 refills) for eligible commercially insured patients experiencing a temporary loss or gap in coverage
Patients participating in government healthcare insurance are not eligible.
Additional Coverage Options
Other forms of assistance may be available, including assistance from independent foundations for patients with government and commercial insurance. myAgios can provide a referral to one of these foundations. Eligibility is determined by the individual foundation. Agios is not affiliated with these organizations.
Please see full Terms and Conditions for more information on each program.
Who are the PSMs and what is their role?
PSMs:
- Have over 20 years of collective experience with rare diseases
- Tailor support for patients and their caregivers based upon their unique needs in living with PK deficiency
- Can direct patients to educational resources about PYRUKYND and PK deficiency, including community connections
- Help patients navigate financial assistance questions and eligibility criteria
- Can be supportive resources and provide assistance through
— Regular phone calls (cadence is approximately monthly)
— Email communications
— Social support via patient webinars with other patients with PK deficiency
When a patient is prescribed PYRUKYND and the enrollment form is faxed to myAgios, the process for support can begin. HIPAA consent must be obtained to complete enrollment into the myAgios program.
This program is not intended as medical advice and patients should consult their healthcare team with questions related to their treatment.
PK=pyruvate kinase.
Learn more about myAgios Patient Support Services
Patient Support ServicesFill out the Enrollment Form online to prescribe PYRUKYND.
Enroll OnlineIt will be automatically processed by myAgios, where a Patient Support Manager (PSM) will then reach out to your patient directly to complete the enrollment.
To learn about disease education support for your patients or their caregivers
PKdeficiency.myAgios.comIndication
PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Important Safety Information
Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.
Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.
Drug Interactions:
- Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
- Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
- Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
- Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
- UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
- P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.
Please see full Prescribing Information for PYRUKYND.
